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Background: Ursolic acid (UA), a plant extract used in traditional Chinese medicine, exhibits potential anticancer
effects in various human cancer cell lines in vitro. In the present study, we evaluated the anti-tumoral properties
of UA against gallbladder carcinoma and investigated the potential mechanisms responsible for its effects on
proliferation, cell cycle arrest and apoptosis in vitro.
Methods: The anti-tumor activity of UA against GBC-SD and SGC-996 cells was assessed using MTT and colony
formation assays. An annexin V/PI double-staining assay was used to detect cell apoptosis. Cell cycle changes were
detected using flow cytometry. Rhodamine 123 staining was used to assess the mitochondrial membrane potential
(ΔΨm) and validate UA’s ability to induce apoptosis in both cell lines. The effectiveness of UA in gallbladder cancer
was further verified in vivo by establishing a xenograft GBC model in nude mice. Finally, the expression levels of cell
cycle- and apoptosis-related proteins were analyzed by western blotting.
Results: Our results suggest that UA can significantly inhibit the growth of gallbladder cancer cells. MTT and colony
formation assays indicated dose-dependent decreases in cell proliferation. S-phase arrest was observed in both cell
lines after treatment with UA. Annexin V/PI staining suggested that UA induced both early and late phases of
apoptosis. UA also decreased ΔΨm and altered the expression of molecules regulating the cell cycle and apoptosis.
In vivo study showed intraperitoneally injection of UA can significantly inhibited the growth of xenograft tumor
in nude mice and the inhibition efficiency is dose related. Activation of caspase-3,-9 and PARP indicated that
mitochondrial pathways may be involved in UA-induced apoptosis.
Conclusions: Taken together, these results suggest that UA exhibits significant anti-tumor effects by suppressing
cell proliferation, promoting apoptosis and inducing 7cell cycle arrest both in vitro and in vivo. It may be a potential
agent for treating gallbladder cancer.
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Gallbladder cancer (GBC) is the most common malig-
nancy of the biliary tract and the 5th most common di-
gestive tract cancer [1]. Owing to a lack of specific signs
and symptoms, many patients are not diagnosed until
the cancer has reached an advanced stage, with local in-
vasion and distant metastasis. As a result, GBC patients
have poor prognoses, and the 5-year survival rate is ap-
proximately 5% [2]. Surgical resection is the only poten-
tially effective treatment for GBC, but recurrence rates
remain high, even after radical resection [3]. In addition,
GBC is resistant to chemotherapy or radiotherapy, hin-
dering the prevention of tumor development and recur-
rence. Novel and more effective chemotherapeutic agentsFigure 1 UA inhibits proliferation in GBC cells. (A) The chemical structu
concentrations of UA for 24, 48 or 72 h. Effects on cell proliferation were d
(n = 3). (C-D) UA inhibits colony formation in GBC cells. GBC-SD and SGC-9
and were allowed to form colonies in fresh medium for 14 days. The photo
in colony formation are shown. Significant differences from the control areare urgently needed to treat GBC. Ursolic acid (UA)
(Figure 1A) is a pentacyclic triterpene acid that can
be extracted from a number of plants, including fruits
and medicinal herbs, and has a variety of clinical ap-
plications. In addition to its antioxidant, anti-hepatitis,
anti-inflammatory and hypolipidemic effects, the most re-
markable property of UA is its anti-tumor activity. UA
inhibits cell growth and induces apoptosis in several
cancers, including colon cancer, breast cancer, leukemia,
melanoma and prostate cancer [4-8]. This cell growth
inhibition is mediated by BAX through the suppression
of the PI3K/Akt pathway. UA downregulates the expres-
sion of STAT3-regulated gene products such as cyclin
D1, Bcl-2, Bcl-xL, survivin, Mcl-1 and VEGF in multiplere of UA. (B) GBC-SD and SGC-996 cells were treated with various
etermined using a MTT assay. Each value represents the mean ± SD
96 cells were treated with different doses of UA (8, 16 or 32 μmol/L)
micrographic differences and number of colonies (mean ± SD, n = 3)
indicated by *p < 0.05 and **p < 0.01.
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UA induces apoptosis through caspase-3 activation con-
comitant with a significant decrease in Bcl-2 and survi-
vin expression [10]. UA also inhibits JNK expression
and IL-2 activation in Jurkat leukemic T cells, resulting
in reduced proliferation and T cell activation [11]. Des-
pite considerable research on the effects of UA on vari-
ous cancers, no detailed studies have investigated the
effects of UA on human gallbladder carcinoma. In the
present study, we confirm the anti-neoplastic activity of
UA in GBC cell lines (including GBC-SD and SGC-996)
and provide insight into the molecular mechanisms un-
derlying this activity. Its tumor growth inhibition effec-
tiveness was further verified by in vivo study.
Results
Effects of UA on the viability of gallbladder carcinoma
cell lines
According to the MTT assay results shown in Figure 1B,
the proliferation of both GBC-SD and SGC-996 cells
was inhibited after treatment with different concentra-
tions of UA for different periods. Furthermore, inhib-
ition was dose- and time-dependent. The groups at 48 h
were chosen to detect changes in molecular events dur-
ing the subsequent experiments. The IC50 values in
GBC-SD and SGC-996 cells at 48 h were approximately
47.6 μmol/L and 28.5 μmol/L, respectively.
Effects of UA on colony formation by gallbladder
carcinoma cell lines
The ability of GBC-SD and SGC-996 cells to form col-
onies in the presence of UA was analyzed using a flat
plate colony formation assay. The results shown in
Figure 1C suggest that UA effectively inhibited colony
formation in both cell lines in a dose-dependent man-
ner. Moreover, statistical analysis demonstrated that the
mean sizes of the control colonies were larger than the
colonies of the drug-treated groups (Figure 1D). This find-
ing suggests that UA may significantly affect GBC-SD and
SGC-996 cell proliferation.
UA-induced cell cycle arrest and apoptosis in gallbladder
carcinoma cell lines
Flow cytometry was used to determine the effects of UA
on cell cycle distribution and apoptosis; the results are
shown in Figure 2. After treatment with UA for 48 h,
the percentage of S-phase cells in GBC-SD colonies was
significantly higher than in the control group (36.84%
and 51.12% in the 50 μmol/L and 60 μmol/L groups, re-
spectively, versus 26.72% in the control group). In addi-
tion, the percentage of S-phase cells in the SGC-996 cell
line was 16.38% in the control group, 21.40% in the
40 μmol/L group, 30.52% in the 50 μmol/L group and
41.63% in the 70 μmol/L group. Both cell lines achievedpeak apoptosis once they were treated with > 50 μmol/L
UA. These results suggest that UA arrests the cell cycle
at the S phase and induces apoptosis in vitro.
Flow cytometric estimation of UA-induced apoptosis
Phosphatidylserine (PS) is located inside normal cells
and is transferred to the surface during the early stage of
cell apoptosis. Annexin V, a Ca2+-dependent phospho-
lipid binding protein, has a strong binding affinity for
PS. Thus, we used an annexin V-FITC/PI staining kit to
assess UA-induced cell apoptosis. The results shown in
Figure 3 indicate a remarkable dose-dependent increase
in both the early and late stages of apoptosis in both cell
lines compared with the control group.
Effects of UA on ΔΨm
To validate the ability of UA to induce apoptosis in
GBC-SD and SGC-996 cells, we performed a cellular func-
tional assay. Rhodamine 123 staining was used to detect
the integrity of the mitochondrial membrane. Loss of
ΔΨm was correlated with a decrease in the intensity of
fluorescent staining. As shown in Figure 4, after UA treat-
ment, the ratio of Rhodamine 123-negative cells increased
from 3.56% to 63.3% in GBC-SD cells and from 5.63% to
98.8% in SGC-996 cells. This increase occurred in a dose-
dependent manner, suggesting that UA induces cancer cell
apoptosis through a mitochondria-dependent mechanism.
Effects of UA on the signal pathway of caspase and Bcl-2
family members
To investigate the molecular mechanism underlying the
apoptotic effects of UA on gallbladder carcinoma cells,
we assessed the expression of several apoptosis-related
proteins, including PARP, caspase-3, caspase-9, cyto-
chrome c, Bax and Bcl-2, by western blot analysis. As
shown in Figure 5, as the concentration of UA in-
creased, Bax protein expression increased, while Bcl-2
expression decreased. The Bax/Bcl-2 ratio increased in
both cell lines, suggesting that these proteins are in-
volved in UA-induced apoptosis. In the caspase pathway,
cleaved caspase-3, −9 and PARP levels were upregulated
after treatment with UA in a dose-dependent manner.
Caspase-3 is a major functional enzyme in the cellular
apoptotic signaling pathway, which suggests that UA may
induce GBC cell apoptosis via caspase-3 activation.
UA suppresses tumor growth in vivo
We successfully established GBC xenograft model in 45
nude mice. To evaluate the anti-tumor effect of UA,
mice in 3 groups were administered UA or vehicle solv-
ent for 21 days.The tumors removed from these mice
are shown in Figure 6A, B, and their mean weights were
provided in Figure 6C. Compare to the control group,
the tumor volume and weight in UA treated group was
Figure 2 UA induces cell cycle arrest at the S phase in GBC cells. GBC-SD and SGC-996 cells were treated with different concentrations of
UA for 48 h. (A) The cell cycle distribution of treated cells was determined using flow cytometry. (B) The data are expressed as the mean ± SD
(n = 3), with results representative of 3 independent experiments shown. *p < 0.05, **p < 0.01 and ***p < 0.001 vs. the control group.
Weng et al. Cancer Cell International 2014, 14:96 Page 4 of 10
http://www.cancerci.com/content/14/1/96significantly reduced, and the reduction is dose related.
These results accord with our in vitro study and further
confirmed the effectiveness of UA in gallbladder cancer.
Discussion
Most malignant tumors remain incurable and are associ-
ated with a poor prognosis. Traditional Chinese medi-
cine (TCM) treats cancer in a unique way compared to
Western medicine. For example, in TCM, the body as a
whole is emphasized, and treatment is focused on modu-
lating the body’s internal environment, including “Blood
Qi” flow and “Yin-Yang” balance [12]. These concepts do
not exist in Western medicine, and thus, therapeutic ef-
fects related to these ideas are not widely accepted.
Recently, the molecular anti-tumor mechanisms of a
large catalogue of traditional Chinese drugs were inves-
tigated, revealing that these drugs have the same anti-
tumor properties as drugs used in Western medicine,
expanding our understanding of TCM and chemotherapy
[13-16].The process of tumor development requires multiple
steps, including cell initiation, proliferation, invasion and
metastasis [17,18]. We have previously identified several
other medicines that inhibit tumor cell proliferation and
induce apoptosis, thereby influencing the process of tu-
mor development [17,19]. In the present study, we in-
vestigated the anti-tumoral properties of UA. The results
of cytology and proteomics experiments allow us to con-
clude for the first time that UA has anticancer properties
in GBC cells similar to those previously observed for
other cancer cell types.
The drug’s cytotoxicity was evaluated using MTT and
colony formation assays. The MTT assay results indicated
that at concentrations > 40 μmol/L, UA significantly inhi-
bited GBC-SD and SGC-996 cell growth in a time- and
dose-dependent manner. The SGC-996 cells were more
sensitive, and an exposure time of 48 h was determined
to be the most suitable for subsequent experiments.
In the colony formation assays, a smaller dose of UA
(>16 μmol/L) effectively inhibited colony formation in
Figure 3 UA induces apoptosis in GBC cells. GBC-SD and SGC-996 cells were treated with different concentrations of UA for 48 h. (A) Flow
cytometric analysis of UA-induced apoptosis in GBC cells using annexin V-FITC/PI staining. Cells in the lower right quadrant represent early
apoptotic cells, and those in the upper right quadrant represent late apoptotic cells. (B) The percentage of apoptotic cells is presented as the
mean ± SD. The data are representative of 3 similar experiments. Significant differences from the control are indicated by *p < 0.05, **p < 0.01
and ***p < 0.001.
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that UA suppresses cancer cell growth. To better under-
stand the effect of UA, flow cytometric analysis was per-
formed. The results of this analysis suggested that UA
causes S-phase arrest in a dose-dependent manner. Cell
cycle arrest may be the mechanism by which UA inhibits
the proliferation of cancer cells.
Apoptosis is an area of intense interest in cancer re-
search. The process of programmed cell death involves a
cascade of molecular events that are initiated by several
stimuli [20]. After confirming the apoptosis-inducing ef-
fects of UA by flow cytometry, we examined the variationin ΔΨm, as mitochondria play an important role in re-
gulating many cellular functions. During the early stage
of cell apoptosis, the permeability of the mitochondrial
membrane is increased, consequently decreasing ΔΨm.
Our study suggests that UA-induced apoptosis is closely
related to this decrease in ΔΨm.
The mitochondrial pathway is one of the three major
pathways involved in apoptosis, and NF-κB is a critical
transcription factor that regulates the transcription of
many genes associated with tumorigenesis [21]. Its target
gene, Bcl-2, is also a central regulator of this process.
Bcl-2 family proteins play key roles in controlling the
Figure 4 UA affects ΔΨm in GBC cells. GBC-SD and SGC-996 cells were treated with UA for 48 h and then stained with the membrane-
sensitive probe Rhodamine 123. (A) Rhodamine retention was measured by flow cytometry. The results are representative of 3 independent
experiments. (B) The corresponding linear diagram shows the percentages of Rhodamine 123-negative cells as the mean ± SD (n = 3). *p < 0.05,
**p < 0.01 and ***p < 0.001 vs. the control group.
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vided mainly into Bax, Bcl-2 and Bid proteins based on
their different biological effects. Bcl-2 is regarded as a
key apoptosis inhibitor which binds to the mitochon-
drion and prevent the release of cytochrome c from the
mitochondria. On the other hand, Bax acts as an apop-
tosis promoter via increase the permeability of the mito-
chondria, which leads to membrane potential loss and
cytochrome c releasing. The destiny of a cell is determined
by the ratio of these two proteins, Bcl-2/Bax. In the pre-
sent study, the Bcl-2/Bax ratio was decreased by treatment
with UA, causing the elevation level of cytochrome c inthe cytosol. Which suggests that UA suppresses NF-κB
nuclear localization and changes the proportion of pro-
apoptotic and anti-apoptosis proteins in Bcl-s family to in-
duce tumor cell apoptosis.
As the Bcl-2/Bax ratio decreases, it can also cause cas-
pase activation and PARP cleavage.Caspase-9 is activated
in the mitochondria-mediated intrinsic pathway. It can
subsequently activate Caspase-3. Caspase-3 is known as
the “executor of apoptosis”. It can mediates apoptosis in
many human cells and in many ways, such as by degrad-
ing anti-apoptosis proteins and cleaving DNA repair mol-
ecules, extracellular matrix proteins, skeleton proteins and
Figure 5 UA modulates the expression of cell cycle- and apoptosis-related proteins in GBC cells. Western blot analysis of protein extracts
from GBC-SD and SGC-996 cells treated with different doses of UA for 48 h. The expression levels of cleaved caspase-3, caspase-9, PARP, cyto c,
Bax and Bcl-2 were analyzed. β-Actin was used as a loading control. The results are representative of 3 independent experiments.
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can systematically dismantle cells by cleaving key proteins
such as PARP. The changes in cleaved caspase-3 and −9
expression observed in our study were consistent with the
changes in cell apoptosis observed after treatment with
UA. PARP cleavage increased accordingly, suggesting the
involvement of a caspase-dependent pathway via caspase-
3 in UA-induced apoptosis.
Conclusion
In summary, our results indicate that UA exhibits potent
anti-GBC properties by suppressing cell proliferation, pro-
moting apoptosis and inducing cell cycle arrest in vitro. It
can also suppresses tumor growth in vivo. Activation of
the mitochondrial-mediated apoptosis pathway is one pos-
sible mechanism responsible for these effects. Our work
provides a new perspective on the function of UA in
tumor chemotherapy, and we believe that further explor-




UA was purchased from Sigma-Aldrich (St Louis, MO,
USA) in the purity of 99.56% and dissolved in dimethylsulfoxide (DMSO). The stock solution was stored at −20°C.
Before use, the drug was defrosted and diluted with cell
culture medium to different concentrations. The following
antibodies were used: rabbit reactive monoclonal anti-
cleaved caspase-3, anti-PARP, anti-Bcl-2 and anti-Bax anti-
bodies and a mouse anti-β-actin antibody. All antibodies
were obtained from Cell Signaling Technology (Danvers,
MA, USA).
Cell lines and culture
The human cell lines GBC-SD and SGC-996 were pur-
chased from the Shanghai Cell Institute Country Cell
Bank. GBC-SD cells were cultured in high-glucose DMEM
(Gibco, USA) at 37°C in a 5% CO2 incubator, while SGC-
996 cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium. Both types of culture medium were
supplemented with 10% fetal bovine serum (Gibco, USA),
penicillin (100 U/mL) and streptomycin (100 U/mL)
(Utah, HyClone, USA).
UA cytotoxicity assay
A drug cytotoxicity assay was performed using the MTT
method. In brief, GBC-SD and SGC-996 cells were placed
in 96-well culture plates at a density of 5 × 103 cells per
well. After culturing overnight, the initial culture medium
Figure 6 UA suppressed the growth of tumor in nude mice injected with GBC-SD cells. (A) GBC-SD cells were subcutaneously injected into
the right flank of the nude mice; The mice were then administered 0.2 mL of vehicle (10% DMSO and 90% PBS) or UA (16 mg/kg and 32 mg/kg)
intraperitoneally everyday for up to 22 days. Photos of 5 representative mice (n = 10) from each group were presented to show the sizes of the
resulting tumors; (B,C) Tumors were excised from the animals and weighed. *P < 0.05 **P < 0.01 vs. the control group.
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centrations of UA (0, 40, 50, 60 or 70 μmol/L) were added.
The cells were further cultured for 24, 48 or 72 h. Then,
40 μL of 5 mg/mL MTT in PBS was added to each well
and incubated for another 4 h. Next, 100 mL of DMSO
was used to dissolve the formazan crystals that formed.
Cell proliferation was evaluated by measuring the optical
density (OD) at 490 nm using an Automated Microplate
Reader (Bio-Tek, USA). The percentage of viable cells was
calculated using the following formula: cell viability (%) =
(OD of treated cells/OD of control cells) × 100. All experi-
ments were repeated three times.
Colony formation assay
GBC-SD and SGC-996 cells in the logarithmic growth
phase were digested using trypsin-EDTA (Gibco, USA)
solution and then seeded in 6-well culture plates at
a density of 500 and 600 cells/well, respectively. After
adherence, the cells were treated with UA (0, 8, 16 or
32 μmol/L) for 48 h, then cultured for 15 days. The cells
were then fixed with methanol and stained with a 5%
Giemsa solution, and colonies (>50 cells) were coun-
ted under an inverted microscope. The reported resultsrepresent the average of 3 independent experiments per-
formed over multiple days.
Cell cycle analysis
GBC-SD and SGC-996 cells were seeded in 6-well plates
at 1.5 × 105 cells/well and treated with UA (0, 40, 50, 60
or 70 μmol/L) for 48 h. Then, the cells were collected,
fixed with cold 70% ethanol and stored at −20°C. After
thawing and centrifugation, the cells were washed with
cold PBS, re-suspended and fixed in 70% ice-cold etha-
nol for 4 h at 4°C, then incubated at 37°C for 30 min
with 10 mg/mL RNase. Finally, 1 mg/mL propidium iodide
(Sigma-Aldrich) was used to stain the cells. DNA content
analysis was performed using flow cytometry (San Diego,
BD, USA). The percentage of cells present in the different
cell cycle phases was determined using Cell Quest acquisi-
tion software (BD Biosciences).
Flow cytometric analysis of cell apoptosis
Cell apoptosis levels were measured with an Annexin
V-FITC apoptosis detection kit (BD Biosciences, USA)
in accordance with the manufacturer’s instructions. In
brief, GBC-SD and SGC-996 cells (105 cells/2 mL/well)
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concentration of UA (0, 40, 50, 60 or 70 μmol/L) for 36 h.
The cells were then collected, resuspended in 100 μL of
1× binding buffer containing 2.5 μL of FITC-conjugated
annexin-V and 1 μL of PI (100 μg/mL) and incubated for
another 15 minutes in the dark. The results were then an-
alyzed using flow cytometry (San Diego, BD, USA).
Detection of variation in the mitochondrial membrane
potential (ΔΨm)
ΔΨm was analyzed by flow cytometry using Rhodamine
123 staining. After treatment with UA (0, 40, 50, 60 or
70 μmol/L) for 48 h, the culture medium was removed,
and cells were washed twice with PBS. The cells were then
incubated in Rhodamine 123 staining solution (5 μg/mL)
for 25 min at 37°C. The samples were analyzed using a
flow cytometer (BD, Biosciences, USA).
Western blotting analysis
GBC-SD and SGC-996 cells (1 × 107) were seeded in a
cell culture dish and treated with different concentra-
tions of UA for 48 h. A BCA assay (Shanghai, Beyotime,
China) was used to determine cell protein concentra-
tions after harvesting the treated cells and extracting
proteins using RIPA buffer according to the method de-
scribed by Levites et al. [25]. For western blot analysis,
equal quantities (50 μg of protein per lane) of total pro-
teins mixed with bromophenol blue (0.01%) were added
in each lane and separated by SDS-PAGE, then electro-
phoretically transferred onto PVDF membranes. The
membrane was blocked in blocking buffer (5% non-fat
dry milk) for 1 h at room temperature, then incubated
with anti-cleaved caspase-3, anti-cleaved caspase-9,
anti-PARP, anti-Bcl-2, anti-Bax, anti-cytochrome c, and
anti-β-actin antibodies in blocking buffer at 4°C over-
night. This was followed by an incubation with a goat
anti-rabbit/anti-mouse secondary antibody conjugated
with horseradish peroxidase (1:5000; Abcam). After each
incubation period, the membranes were washed three
times with TBS/T. The immunoreactive bands were visu-
alized using a chemiluminescent HRP substrate (ECL; GE
Healthcare), then scanned and quantified with a Gel Doc
2000 (BioRad, USA). The results are representative of 3
independent experiments.
In vivo efficacy of UA
Six- to eight-week-old mail athymic nude mice were pur-
chased from Shanghai SLAC Laboratory Animal Co., Ltd.
(Shanghai, China). They were maintained in a pathogen-
free environment. All experimental procedures were pre-
formed strictly follow the international ethical guidelines
and the National Institutes of Health Guide concerning
the Care and Use of Laboratory Animals and were ap-
proved by the institutional guidelines of Shanghai JiaotongUniversity (Shanghai, China). To establish a tumor xeno-
graft model, 2x106 GBC-SD cells in log-phase growth
were suspended in 0.1 ml serum-free culture medium and
subcutaneously injected into the left axilla of all nude
mice. After 24 hours, 45 mice were randomly divided into
3 groups (15 mice/group). Mice in the first group were
treated with vehicle solvent (10% DMSO and 90% PBS) in-
traperitoneally. UA in a dose of 16 mg/kg and 32 mg/kg
was intraperitoneally injected into the mice of other two
groups everyday. On day 22, all mice were sacrificed, the
tumor was harvested and weighed. 5 mice in each group
were randomly chose to be shown in the figure.
Statistical analysis
Each experimental value was expressed as the mean ±
standard deviation (SD). All statistical analyses were per-
formed using SPSS16.0 software. The differences between
groups were assessed by Student’s t-test and were con-
sidered significant when the p value was less than 0.05.
Statistical significance is denoted as follows: *p < 0.05,
**p < 0.01, and ***p < 0.001. All data points represent
the mean of triplicate data points.
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